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INTRODUCTION
Some inflammatory biomarkers including Interleukin (IL)-6, IL-
18 and C-reactive protein (CRP) have been shown to be associated
with increased risk of type 2 diabetes (1, 2), cardiovascular dis-
ease (3-5), and many types of cancer (6-9). Dietary factors can
modulate inflammatory status by suppressing immune responses
(10).
Consumption of soy foods has been shown to have beneficial ef-
fects on various aspects of human health including reduced risk of
inflammation-related diseases, such as cardiovascular disease (11,
12), diabetes (13), and certain types of cancers (14, 15). Soy and soy
isoflavone have been shown to inhibit cell adhesion molecule ex-
pression in cultured endothelial cells (16, 17), reduce production of
proinflammatory cytokines, and decrease oxidative stress in ani-
mal models (18-22). Several recent clinical trials have shown that a
soy-rich diet substantially lowers the levels of interleukin IL-6,
CRP, and IL-18 (12, 23), although results are somewhat inconsis-
tent (24, 25).
Soy foods are divided into fermented products (miso and natto)
and non-fermented products based on their manufacturing proc-
ess. Some studies have shown that components of fermented soy
products maintain the functions of various organs and prevent
coronary heart disease (26, 27). Fermented soy foods have been
shown to contain greater amounts of polyamines including sper-
midine than the amounts in non-fermented soy products, and
polyamines have been shown to be associated with cardioprotec-
tion and lifespan extension (28, 29). Recently, two cross-sectional
studies were conducted in Japanese, and it was shown that natto
intake had a significant inverse association with the risk of mortality
from cardiovascular disease (30) and that intake of fermented soy
foods (miso and natto) had an inverse association the develop-
ment of high blood pressure in a population with normal blood
pressure (31).
In this study, we examined the associations of soy foods (total,
fermented soy foods, non-fermented soy foods, soy isoflavone)
with high-sensitivity (hs)-CRP, IL-6, and IL-18 levels in workers in
Tokushima Prefecture of Japan. We also examined associations
between each soy food levels of and hs-CRP, IL-6 and IL-18.
MATERIALS AND METHODS
Study population
The study population consisted of participants in epidemiologi-
cal research, including 1,460 men and women, who were recruited
from Japanese workers in Tokushima Prefecture in 2010. We ex-
cluded participants who had missing data for potential confounders
including history of stroke (n = 1), smoking habit (n = 1), drinking
habit (n = 3), regular exercise (n = 4) and past or current history of
allergic disease (n = 3). We also excluded participants who had
missing data for inflammatory markers including hs-CRP (n = 1),
IL-6 (n = 2) and IL-18 (n = 2). Two participants with missing data for
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HbA1c (n = 1) and glucose (n = 1) were also excluded. Fifteen
participants with a total energy intake exceeding mean3 stan-
dard deviations,3,513 kcal/day for men (n = 13) and2,947
kcal/day for women (n = 2), were also excluded. Finally, data for a
total of 1,426 adults (1,053 men and 373 women) aged 20-64 years
were used for analysis.
All participants had valid data with a completed questionnaire,
physical measurements and a written informed consent form. The
study protocol was approved by institutional review board of the
Tokushima University Hospital.
Measurement of biomarkers
A fasting blood sample was obtained from each participant by
trained staff. Glucose level was determined by using the glucose
oxidase-peroxidase method (ADAMS glucose GA-1170, ARKRAY
Inc. Kyoto, Japan). High-sensitivity hs-CRP concentration was de-
termined by using a commercially available latex turbidimetric im-
munoassay (LT CRP-HS II, Wako Pure Chemical Ltd., Osaka,
Japan). HbA1c was determined by using the high-performance
liquid chromatography method (HLC-723G11, Tosoh Corp. Inc.
Tokyo, Japan). IL-6 concentration was determined using the
chemiluminescent enzyme immunoassay (Human IL-6 CLEIA,
Fujirebio, Inc., Tokyo, Japan). IL-18 concentration was deter-
mined by using the enzyme-linked immunosorbent assay (Human
IL-18 ELISA Kit, Medical & Biological Laboratories Co., Ltd.,
Nagoya, Japan).
Food intake
Habitual soy food intake was estimated using a validated quantita-
tive food-frequency questionnaire (32). The questionnaire in-
cluded 12 common soy food items : miso (soybean paste), soy
sauce, natto (fermented soybean), tofu, soy milk, fried tofu, yuba
(dried bean cured), okara (soybean cured refuse) and green soy
bean, bean sprouts and kinako (soy flour), ganmodoki (fried bean
cured with vegetable). We defined miso, soy sauce and natto as
fermented soy foods. Other soy foods were defined as non-fer-
mented soy foods. Nutritional calculation was performed accord-
ing to the Standard Tables of Food Composition in Japan. The
amount of total isoflavone intake was determined by using a data-
base with isoflavone contents in soy foods (33). Food and energy
intake was estimated by the validated FFQ method (34). The ques-
tionnaire included questions on 29 food items and 10 cooked meals.
We estimated food intake for each of 18 food groups.
Other variables
We obtained covariates from the standardized questionnaires,
including sociodemographic characteristics (age, sex), lifestyle
behaviors (alcohol consumption, smoking, exercise habits, and
intake of vegetables, fresh fruits, and fish), personal health and
medical history (hypertension, diabetes, allergy, and stroke).
Trained staff measured body weight, height, and blood pressure
using calibrated instruments. Hypertension was defined as systolic
blood pressure of more than 140 mm Hg, diastolic blood pres-
sure of more than 90 mm Hg, or self -reports of hypertension
medicine usage. Allergy was self -reported diagnosis of an allergy.
Prevalent diabetes was defined as a measured fasting blood glu-
cose concentration of 126 mg/dL, HbA1c level of 6.5% or more, or
self -reports of diabetes medicine usage.
Statistical analysis
We performed analysis on the basis of energy-adjusted intake
using the density method (amount of food intake per 1,000 kcal of
energy) for all soy food items, vegetables, fruits, and fish. The
subjects were divided into quintiles with almost the same num-
ber of subjects in each category. The values of inflammatory
markers were log-transformed to be a normal distribution. Con-
tinuous variables are expressed as means and standard deviations,
and categorical variables are expressed as proportion (%). ANOVA
and the chi -square test were used to compare characteristics
among the quintiles of dietary soy fermented intake.
General linear models were used to evaluate the associations of
dietary total soy food, fermented soy food, non-fermented soy food
and total soy isoflavone intake with inflammatory markers after
adjusting for the following probable covariates in three different
models. Model 1 was adjusted for age. Model 2 was model 1 plus
adjustments for BMI (logarithm), current smoker (yes or no), cur-
rent drinker (yes or no), regular exerciser (yes or no), diabetes
(yes or no), hypertension (yes or no), allergic disease (yes or no),
and total energy intake. Model 3 was model 2 plus adjustments for
vegetable intake, fruit intake and fish intake. Multiple regression
analyses were used to evaluate the association between intake of
each of the 12 soy food items and inflammatory makers. P values
0.05 were considered statistically significant using two-tailed tests.
All analyses were conducted using IBM SPSS Statistics (version
24.0).
RESULTS
Characteristics of men and women according to quintiles of total
fermented soy food intake
The mean ages of the participants were 40.29.7 years for men
and 38.79.8 years for women, and mean BMIs were 23.83.3
kg/m2 for men and 21.43.1 kg/m2 for women. The estimated
daily energy levels were 1,848443 kcal/day for men and 1,711
375 kcal/day for women. The characteristics of the 1,426 partici-
pants (1,053 men and 373 women) according to quintiles of energy-
adjusted soy fermented food intake are shown in Table 1. Re-
garding nutrient intake, men in the highest quintile of the fer-
mented soy food group had less energy intake and higher intake
levels of non-fermented soy food, vegetables, fruits and fish than
did men in the lowest quintile. In addition, men in the highest
quintile of the fermented soy food group were olderer than men in
the lowest quintile. Women in the highest quintile of the fer-
mented soy food group had lower percentage of current drinkers
and higher intake levels of non-fermented soy food, vegetables,
fruits and fish than did women in the lowest quintile (Table 1). In
the study population including men and women, there was a 7.9-
fold difference in total soy fermented food intake between the
highest and lowest quintiles (median : 24.5g/d in the highest quin-
tile vs. 3.1 g/d in the lowest quintile).
Multivariate-adjusted mean (and 95% CI) of inflammatory mark-
ers by quintiles of soy food intake
We investigated associations between levels of inflammatory
markers and soy food intake using the general linear models in
men and women. A higher level of fermented soy food intake was
associated with 10% lower IL-6 concentration between the highest
and lowest quintiles (Q1 : 1.04 pg/mL, Q5 : 0.94 pg/mL ; P for
trend = 0.019) in men. Further adjustment for smoking, alcohol
consumption, exercise, diabetes, allergy and energy intake plus
intake of vegetable, fruits and fish did not alter the results (Q1 : 1.03
pg/mL, Q5 : 0.94 pg /mL ; P for trend = 0.031). An inverse associa-
tion was found between serum IL-6 concentration and fermented
soy food intake, but this inverse association was not found for total
soy food or non-fermented soy food in men. In addition, soy intake
including total soy food, non-fermented soy food and soy isofla-
vone did not affect serum concentrations of hs-CRP, IL-6 and IL-
18. In contrast to the results found for men, no difference was found
for women (Table 2).
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Multiple regression analysis for inflammatory markers by intake
of each soy food
We examined associations between 12 items of soy food and
inflammatory markers using multiple regression analyses (Table 3).
In men, after multivariable adjustment, IL-6 showed significant
negative associations with miso (β = -0.068, p =0.034) and soy
sauce (β = -0.074, p = 0.018) intake, but hs-CRP and IL-18 showed
no associations. For women, significant positive associations were
found between tofu intake and IL-6 concentration (β = 0.107, p =
0.049) and between soy milk intake and serum hs-CRP concentra-
tion (β = 0.104, p = 0.049).
DISCUSSION
We found that intake of fermented soy foods including miso and
soy sauce was associated with reduction of serum IL-6 level
(Tables 2 and 3). The mechanisms by which fermented soy foods
and their constituents affect inflammatory biomarkers in men re-
main to be clarified. Although human studies on anti - inflammatory
effects of fermented soy products are limited, animal studies have
shown anti - inflammatory properties of fermented soy products.
Meju is a naturally fermented soy block used to produce soy paste
and soy sauce in Korea. Feeding mice fermented soybean fibers
from meju reduced plasma cholesterol and triglyceride levels, adi-
pocyte size and hepatic lipid accumulation. Levels of plasma C-
reactive protein, TNF-α and IL-6 were also significantly reduced in
mice treated with meju components (35). Furthermore, two studies
have shown that fermented soy products suppress inflammation
in a gut inflammatory bowel disease model. Kawahara et al. exam-
ined the effect of fermented soy milk with Lactococcus lactis subsp.
Lactis S-SU2 on dextran sodium sulfate- induced colitis and found
that treatment with fermented soy milk reduced the clinical se-
verity score in a colitis model (36). In another study, treatment
with fermented soy germ extract improved the severity of colitis,
enhanced gut permeability and suppressed IL-1β production in
2, 4, 6 - trinitrobenzen sulphonic acid- induced colitis (37).
In the present study, intake of fermented soy products was evalu-
ated as the sum intake of miso, soy sauce and natto. Functional
effects of fermented soy products have been studied. Soy sauce has
anti -microbial activity, an anti -hypertensive effect, an anti -carci-
nogenic effect and anti -platelet activity (38). Natto contains inhibi-
tors against the angiotensin-converting enzyme and thereby might
have an anti -hypertensive effect (39). In an obese db/db mouse
model, fermented soybean extracts reduced serum total cholesterol
and LDL cholesterol levels (40). In a human study by Sapbamrer et
al. on the effects of dietary traditional fermented soybean intake on
BMI, reproductive hormones, lipids and glucose in postmeno-
pausal women, it was found that treatment with fermented soy-
beans for 6 months had favorable effects on progesterone and cho-
lesterol (42). In two prospective cohort studies targeting Japanese, it
Table 1 Characteristics of men and women according to quintiles of total fermented soy food intake
Energy adjusted total fermented soy food (quintiles)
Men
P
Women
P
Q1 (n = 195) Q3 (n = 211) Q5 (n = 221) Q1 (n = 90) Q3 (n = 75) Q5 (n = 64)
Age, yearsa 37.59.9 39.39.0 42.79.7 .001 37.09.1 39.29.5 39.69.7 0.059
BMI, kg/m2 a 23.93.3 23.73.4 23.93.5 0.713 21.53.4 21.42.6 21.33.4 0.996
Past history or current treatmentb
Diabetes, n (%) 8(4.1) 6(2.8) 10(4.5) 0.898 2(2.2) 0(0.0) 0(0.0) 0.597
Hypertension, n (%) 31(15.9) 48(22.7) 46(20.8) 0.287 8(8.9) 5(6.7) 4(6.3) 0.752
Allergic, n (%) 72(36.9) 92(43.6) 100(45.2) 0.459 50(55.6) 39(52.0) 37(57.8) 0.959
Current Smoker, n yes (%)b 72(36.9) 66(31.3) 80(36.2) 0.782 10(11.1) 2(2.7) 5(7.8) 0.136
Current Drinker, n yes (%)b 103(52.8) 128(60.7) 139(62.9) 0.098 27(30.0) 20(26.7) 24(37.5) 0.015
Regular exerciser, n yes (%)b 101(51.8) 101(47.9) 105(47.5) 0.517 55(61.1) 40(53.3) 26(40.6) 0.170
Dietary intakea,c
Total energy, kcal/day 1929482 1898413 1732427 .001 1726384 1750413 1675361 0.751
Total soyfood, g/1000 kcal/day 36.729.4 56.332.2 85.748.3 .001 43.447.2 51.724.3 92.747.0 .001
Fermented soy food, g/1000 kcal/day 3.21.4 9.90.9 24.78.9 .001 2.91.3 9.90.9 23.88.5 .001
Non- fermented soy food, g/1000 kcal/day 33.529.4 46.432.2 61.045.6 .001 40.547.0 41.824.2 67.643.1 0.001
Total soy isoflavone, mg/1000 kcal/day 7.66.4 13.57.6 24.212.6 .001 9.110.9 12.84.7 25.311.5 .001
Miso, g/1000 kcal/day 2.01.4 7.02.4 13.36.9 .001 1.81.2 6.62.8 13.28.2 .001
Soy sauce, g/1000 kcal/day 0.90.9 1.51.3 2.72.7 .001 0.70.6 1.31.1 2.43.4 .001
Natto, g/1000 kcal/day 0.30.6 1.41.9 8.89.6 .001 0.40.8 2.02.5 8.38.0 .001
Vegetables,g/1000 kcal/day 56.537.0 73.339.0 85.943.3 .001 85.444.7 89.037.5 109.063.8 0.015
Fruits, g/1000 kcal/day 15.120.3 21.029.9 20.722.6 .001 27.633.1 30.728.2 32.429.3 .001
Fish, g/1000 kcal/day 22.516.7 28.516.0 33.519.4 0.001 24.616.0 29.717.5 31.517.1 0.053
Inflammatory biomarkera
hs -CRP, mg/dL 0.080.14 0.120.30 0.100.36 0.608 0.030.05 0.040.04 0.050.17 0.244
IL-6, pg/mL 1.200.90 1.111.06 1.110.87 0.027 1.050.66 1.262.01 1.010.94 0.693
IL-18, ng/L 221.577.6 202.961.7 215.862.5 0.052 170.555.5 164.461.9 171.047.7 0.870
Values are meansSDa or number and percentagesb. men (n = 1,053), women (n = 373).
Q, quintiles ; BMI,Body mass index ; hs -CRP, high-sensitivity C-reactive protein ; IL -6, Interleukin-6 ; IL -18, Interleukin-18.
Dietary intakes were adjusted for total energy using the density methodc.
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Table 2 Multivariate -adjusted mean (and 95% CI) of inflammatory markers by quintiles of soy food intake
Energy adjusted soy food intake (quintiles)
Men
P - trend
Women
P - trendQ1 Q3 Q5 Q1 Q3 Q5
Adjusted
Means (95% CI)
Adjusted
Means (95%CI)
Adjusted
Means (95%CI)
Adjusted
Means(95%CI)
Adjusted
Means (95%CI)
Adjusted
Means (95%CI)
Total soy food n = 211 n = 223 n = 207 n = 74 n = 63 n = 78
hs -CRP, mg/dL
Medle 1 0.05 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.03 - 0.05) 0.611 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.924
Medle 2 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.04 - 0.05) 0.530 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.969
Medle 3 0.05 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.03 - 0.05) 0.468 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.970
IL -6,pg/mL
Medle 1 1.05 (0.97 - 1.13) 1.00 (0.93 - 1.07) 0.96 (0.89 - 1.03) 0.394 0.95 (0.84 - 1.08) 0.85 (0.74 - 0.98) 0.87 (0.77 - 0.99) 0.742
Medle 2 1.04 (0.96 - 1.11) 1.01 (0.94 - 1.09) 0.96 (0.89 - 1.03) 0.635 0.94 (0.83 - 1.06) 0.87 (0.76 - 1.00) 0.88 (0.78 - 1.00) 0.929
Medle 3 1.04 (0.97 - 1.12) 1.02 (0.95 - 1.09) 0.96 (0.89 - 1.03) 0.554 0.94 (0.83 - 1.06) 0.86 (0.76 - 0.99) 0.89 (0.78 - 1.00) 0.929
IL -18,ng/L
Medle 1 210.4 (202.4 - 219.0) 205.6 (197.8 - 213.5) 203.2 (195.2 - 211.5) 0.794 164.1 (154.8 - 174.0) 160.7 (152.2 - 169.9) 167.9 (158.7 - 177.8) 0.611
Medle 2 208.4 (200.8 - 216.6) 206.5 (199.2 - 214.3) 204.2 (196.6 - 212.4) 0.898 163.3 (154.3 - 172.9) 157.4 (148.0 - 167.6) 166.7 (157.8 - 176.5) 0.605
Medle 3 207.5 (199.6 - 215.6) 206.5 (199.2 - 214.4) 205.1 (197.4 - 213.5) 0.929 163.3 (154.3 - 173.0) 156.7 (147.2 - 166.7) 167.1 (157.9 - 176.9) 0.596
Fermented soy food n = 195 n = 211 n = 221 n = 90 n = 75 n = 64
hs -CRP, mg/dL
Medle 1 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.04 - 0.05) 0.885 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.444
Medle 2 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.04 - 0.05) 0.824 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.296
Medle 3 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.04 - 0.05) 0.721 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.313
IL -6, pg/mL
Medle 1 1.04 (0.96 - 1.13) 0.94 (0.87 - 1.01) 0.94 (0.87 - 1.01) 0.019 0.92 (0.82 - 1.03) 0.91 (0.80 - 1.03) 0.81 (0.71 - 0.94) 0.524
Medle 2 1.03 (0.95 - 1.11) 0.95 (0.88 - 1.02) 0.94 (0.88 - 1.01) 0.039 0.89 (0.80 - 1.00) 0.91 (0.81 - 1.03) 0.82 (0.72 - 0.94) 0.637
Medle 3 1.03 (0.95 - 1.11) 0.95 (0.88 - 1.02) 0.94 (0.87 - 1.01) 0.031 0.89 (0.79 - 0.99) 0.92 (0.81 - 1.03) 0.81 (0.71 - 0.93) 0.566
IL -18, ng/L
Medle 1 213.3 (204.9 - 222.4) 195.9 (188.4 - 203.7) 205.1 (197.3 - 213.0) 0.036 164.8 (156.1 - 173.7) 157.8 (148.8 - 167.1) 165.2 (155.3 - 176.1) 0.662
Medle 2 212.8 (204.4 - 221.1) 197.2 (190.0 - 204.8) 204.6 (197.0 - 212.2) 0.075 162.9 (154.6 - 171.7) 157.8 (149.1 - 167.0) 167.1 (157.0 - 177.5) 0.693
Medle 3 211.8 (203.3 - 220.3) 197.2 (190.0 - 204.8) 205.1 (197.5 - 212.9) 0.105 162.6 (154.2 - 171.2) 158.1 (149.6 - 167.5) 167.5 (157.6 - 178.3) 0.688
Non - fermented soy food n = 209 n = 220 n = 203 n = 76 n = 66 n = 82
hs -CRP, mg/dL
Medle 1 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.06) 0.04 (0.04 - 0.05) 0.382 0.02 (0.02 - 0.03) 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.842
Medle 2 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.06) 0.04 (0.04 - 0.05) 0.515 0.02 (0.02 - 0.03) 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.977
Medle 3 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.06) 0.04 (0.04 - 0.05) 0.454 0.02 (0.02 - 0.03) 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.967
IL -6, pg/mL
Medle 1 1.00 (0.93 - 1.08) 0.98 (0.91 - 1.05) 0.97 (0.90 - 1.05) 0.180 0.92 (0.81- 1.04) 0.90 (0.78 - 1.03) 0.87 (0.78 - 0.99) 0.829
Medle 2 1.00 (0.93 - 1.07) 0.99 (0.92 - 1.06) 0.98 (0.91 - 1.06) 0.415 0.91 (0.80 - 1.03) 0.90 (0.79 - 1.02) 0.87 (0.78 - 0.98) 0.935
Medle 3 1.00 (0.93 - 1.08) 0.99 (0.92 - 1.06) 0.98 (0.91 - 1.05) 0.357 0.91 (0.80 - 1.03) 0.89 (0.78 - 1.01) 0.88 (0.78 - 0.99) 0.945
IL -18, ng/L
Medle 1 208.0 (200.0 - 216.5) 203.2 (195.7 - 211.3) 204.6 (196.6 - 213.1) 0.807 163.7 (154.4 - 173.3) 162.6 (152.8 - 172.8) 171.0 (161.9 - 180.9) 0.295
Medle 2 207.5 (199.6 - 215.4) 204.2 (196.7 - 211.7) 206.5 (198.6 - 214.6) 0.984 163.3 (154.2 - 172.6) 162.6 (153.1 - 172.8) 169.8 (160.8 - 179.2) 0.442
Medle 3 206.5 (198.6 - 214.5) 204.2 (196.6 - 211.7) 207.5 (199.5 - 215.8) 0.981 162.9 (154.1 - 172.6) 162.6 (153.0 - 172.7) 169.8 (160.8 - 179.5) 0.464
Soy isoflavone n = 209 n = 213 n = 209 n = 76 n = 73 n = 76
hs -CRP, mg/dL
Medle 1 0.05 (0.04 - 0.05) 0.05 (0.04 - 0.05) 0.04 (0.04 - 0.05) 0.736 0.03 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.03 (0.02 - 0.03) 0.659
Medle 2 0.04 (0.04 - 0.05) 0.05 (0.04 - 0.06) 0.04 (0.04 - 0.05) 0.604 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.03 (0.02 - 0.03) 0.605
Medle 3 0.05 (0.04 - 0.05) 0.05 (0.04 - 0.06) 0.04 (0.04 - 0.05) 0.572 0.02 (0.02 - 0.03) 0.02 (0.02 - 0.03) 0.03 (0.02 - 0.03) 0.593
IL -6, pg/mL
Medle 1 1.06 (0.98 - 1.14) 1.01 (0.94 - 1.09) 0.95 (0.88 - 1.03) 0.324 0.93 (0.82 - 1.05) 0.89 (0.78 - 1.01) 0.84 (0.74 - 0.95) 0.787
Medle 2 1.04 (0.97 - 1.12) 1.03 (0.95 - 1.10) 0.96 (0.89 - 1.03) 0.598 0.92 (0.82 - 1.05) 0.91 (0.80 - 1.03) 0.86 (0.76 - 0.98) 0.863
Medle 3 1.05 (0.97 - 1.13) 1.03 (0.95 - 1.10) 0.95 (0.88 - 1.03) 0.521 0.92 (0.81 - 1.04) 0.91 (0.80 - 1.03) 0.86 (0.76 - 0.98) 0.911
IL -18, ng/L
Medle 1 212.8 (204.4 - 221.2) 202.3 (194.7 - 210.6) 205.1 (197.0 - 213.2) 0.480 161.1 (152.2 - 170.8) 154.2 (145.5 - 163.6) 168.3 (158.8 - 178.2) 0.266
Medle 2 209.9 (202.0 - 218.1) 203.7 (196.1 - 211.3) 206.1 (198.3 - 214.0) 0.639 160.7 (152.0 - 170.2) 154.9 (146.2 - 164.0) 169.0 (159.7 - 178.9) 0.263
Medle 3 208.4 (200.6 - 216.9) 203.2 (196.0 - 211.2) 207.0 (199.2 - 215.3) 0.650 160.3 (151.3 - 169.6) 153.8 (145.4 - 163.1) 169.8 (160.3 - 179.6) 0.168
Men (n = 1,053), women (n = 373).
All values are adjusted mean inflammatory markers ; 95% confidence interval in parentheses.
Model1 : adjusted for age (continuous).
Model 2 : model 1 plus adjusted for BMI ((logarithm), current smoker (y/n), current drinker (y/n), regular exerciser (y/n), diabetes (y/n), hypertension (y/n),
allergic (y/n), and energy intake (continuous).
Model 3 : model 2 plus adjusted for vegetables, friuts and fish intake (continuous).
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was shown that intake of fermented soy foods including miso and
natto was inversely associated with the development of high blood
pressure in both men and women with normal blood pressure and
that natto intake reduced the risk of cardiovascular disease mortality
(30, 31).
Although intervention studies have been carried out to deter-
mine the relationships between soy, soy isoflavone and inflam-
mation status, the results are not consistent. Reverri et al. con-
ducted a randomized, controlled, cross-over study to evaluate the
effects of soy nut consumption on inflammatory biomarkers and
endothelial function. In that study, they measured CRP, TNF-α,
IL-6, IL-18, IL-10 and oxide LDL levels after 4 weeks of interven-
tion, but they did not found a significant difference in any biomarker
(42). Jenkins et al. examined the effects of high (73 mg/day) and
low (10 mg/day)- isoflavone soy protein foods on acute-phase pro-
teins and proinflammatory cytokines in men and women. A high
level of isoflavone intake increased the serum concentration of IL-6
but not that of CRP or TNF-α in women. In men, a difference in
serum cytokine concentrations was not found (43). Mangano et al.
evaluated the long-term effects of soy protein and/or soy isofla-
vone supplementation on serum lipids and inflammatory markers
in women over 60 years of age in a 1-year randomized, double-
blind placebo-control, clinical trial. Interestingly, it was found that
soy protein significantly decreased the level of the inflammatory
maker IL-6 and that soy isoflavones tended to decrease IL-6 level.
No difference was found in the inflammatory maker CRP (44). In
our study, an inverse association was not found between intake of
soy foods and/or soy isoflavone and inflammatory markers (Table 2).
Considering previous studies and our study, soy foods and/or soy-
derived constituents might influence each inflammatory makers
differently.
The reason why the effects of fermented and non-fermented soy
products on inflammatory makers are different is not clear. At least,
soy isoflavones cannot explain the discrepancy because intake of
soy isoflavone derived from non-fermented soy products is higher
than that derived from fermented soy products. Kim et al. exam-
ined the relationships of fermented soy food consumption and
non-fermented soy food consumption with gastric cancer by a
meta-analysis. It was shown that a high intake of fermented soy
foods was significantly associated with an increased risk of gastric
cancer, whereas an increased intake of non-fermented soy foods
was significantly associated with a decreased risk of gastric cancer
(45). The results of that study indicate the possibility that the ef-
fects of fermented soy food are different from those of non-
fermented soy food in some aspects.
Our study shows the associations between intake of fermented
soy food and inflammatory markers, but our study has some limita-
tions. First, because of the cross-sectional design, we cannot infer
causality from our results. Second, despite extensive adjustments
for potential confounding factors, we cannot rule out the possibility
that part of the observed associations might be related to a healthy
lifestyle and/or other bioactive compounds not examined in this
study. In this study, high level of tofu intake and soymilk intake
were associated with increased IL-6 and hs-CRP concentrations,
Table 3 Multiple regression analysis for inflamatory markers by intake of each soy food
Log hs -CRP, mg/dL Log IL -6, pg/mL Log IL -18, ng/L
Unstandardised
coefficients
Standardised
coefficients P
Unstandardised
coefficients
Standardised
coefficients P
Unstandardised
coefficients
Standardised
coefficients P
B SE β B SE β B SE β
Men Miso, g/1000 kcal/day 0.000 0.003 - 0.001 0.965 - 0.003 0.001 - 0.068 0.034 - 0.001 0.001 - 0.023 0.467
Soy sauce, g/1000 kcal/day 0.001 0.008 0.003 0.922 - 0.010 0.004 - 0.074 0.018 0.001 0.002 0.015 0.628
Natto, g/1000 kcal/day - 0.005 0.002 - 0.057 0.057 - 0.002 0.001 - 0.039 0.210 0.000 0.001 - 0.002 0.954
Tofu, g/1000 kcal/day 0.000 0.001 0.006 0.832 0.000 0.000 - 0.027 0.392 0.000 0.000 0.018 0.558
Soy milk, g/1000 kcal/day - 0.001 0.001 - 0.028 0.345 0.000 0.000 0.027 0.377 0.000 0.000 - 0.006 0.851
Fried tofu, g/1000 kcal/day - 0.002 0.012 - 0.006 0.849 - 0.003 0.006 - 0.015 0.630 - 0.004 0.003 - 0.034 0.261
Dried bean cured, g/1000 kcal/day - 0.302 0.237 - 0.038 0.204 - 0.151 0.128 - 0.036 0.241 - 0.007 0.067 - 0.003 0.917
Soybean cured refuse, g/1000 kcal/day - 0.012 0.010 - 0.038 0.201 - 0.002 0.005 - 0.013 0.664 - 0.002 0.003 - 0.023 0.446
Green soy bean, g/1000 kcal/day 0.001 0.003 0.005 0.858 - 0.002 0.002 - 0.033 0.282 0.000 0.001 0.008 0.792
Bean sprouts, g/1000 kcal/day - 0.001 0.001 - 0.026 0.382 0.000 0.001 0.004 0.901 0.000 0.000 - 0.020 0.510
Soy flour, g/1000 kcal/day 0.003 0.055 0.002 0.959 0.022 0.029 0.023 0.463 0.000 0.015 0.001 0.984
Fried bean cured with vegetable, g/1000 kcal/day - 0.004 0.006 - 0.019 0.529 - 0.002 0.003 - 0.024 0.432 - 0.003 0.002 - 0.049 0.107
Women Miso, g/1000 kcal/day 0.002 0.004 0.023 0.680 - 0.001 0.002 - 0.018 0.741 0.002 0.001 0.103 0.068
Soy sauce, g/1000 kcal/day 0.003 0.013 0.012 0.820 - 0.011 0.007 - 0.081 0.136 - 0.002 0.003 - 0.025 0.653
Natto, g/1000 kcal/day - 0.001 0.005 - 0.013 0.812 - 0.004 0.003 - 0.071 0.186 0.000 0.001 - 0.014 0.794
Tofu, g/1000 kcal/day 0.001 0.001 0.035 0.521 0.001 0.001 0.107 0.049 0.001 0.000 0.090 0.106
Soy milk, g/1000 kcal/day 0.002 0.001 0.104 0.049 0.000 0.000 0.048 0.364 0.000 0.000 0.021 0.691
Fried tofu, g/1000 kcal/day 0.004 0.014 0.018 0.749 0.012 0.008 0.088 0.114 0.001 0.004 0.009 0.877
Dried bean cured, g/1000 kcal/day 0.959 0.768 0.067 0.213 0.371 0.443 0.045 0.402 - 0.021 0.207 - 0.006 0.918
Soybean cured refuse, g/1000 kcal/day 0.014 0.016 0.045 0.407 - 0.003 0.009 - 0.019 0.723 - 0.004 0.004 - 0.056 0.306
Green soy bean, g/1000 kcal/day 0.000 0.008 0.000 0.996 0.000 0.005 - 0.001 0.980 - 0.002 0.002 - 0.059 0.313
Bean sprouts, g/1000 kcal/day - 0.002 0.001 - 0.088 0.105 0.000 0.001 - 0.014 0.791 - 0.001 0.000 - 0.106 0.055
Soy flour, g/1000 kcal/day 0.005 0.056 0.005 0.930 - 0.032 0.032 - 0.052 0.329 0.018 0.015 0.065 0.238
Fried bean cured with vegetable, g/1000 kcal/day 0.012 0.011 0.059 0.280 - 0.006 0.006 - 0.051 0.352 - 0.001 0.003 - 0.027 0.627
Men (n = 1,053), women (n = 373). Each soy food intake was adjusted for total energy using the density method.
Adjusted for age (continuous), BMI (logarithm), current smoker (y/n), current drinker (y/n), regular exerciser (y/n), hypertension (y/n),
allergic (y/n), and energy intake (continuous), vegetables, friuts and fish intake (continuous).
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respectively (Table 3). These findings are unexpected. Third, we
used a food-frequency questionnaire to estimate participants’ die-
tary intake. The questionnaire is not a measure of absolute intake
but is suited for classifying individuals into intake categories and is
the most commonly used approach for assessing intake in epide-
miological studies. Measurement error in reporting might lead to
random errors that could dilute the real associations between soy
foods and inflammatory markers. Fourth, as with any observational
study, observed associations might be in part due to residual con-
founding despite extensive adjustment for known confounding fac-
tors. Lastly, the sample size was small and all of the subjects were
Japanese, so applicability to other populations is unclear.
In conclusion, we found that high intake levels of fermented soy
foods including miso and soy sauce in men were associated with a
reduction in serum IL-6 level, which has been shown to be associ-
ated with many chronic diseases. We did not observe any effect of
soy foods on IL-18 in level in men or women. Further study is
needed to confirm the effects of fermented soy foods on inflamma-
tory markers.
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